Last reviewed · How we verify
NCT04154761: CAVARESECT
Resection of the Inferior Vena Cava Due to Tumor Involvement
trial testing Resection of inferior vena cava and reconstruction in Neoplasms in 13 participants. Completed in 1 October 2019.
1 September 2019
Quick facts
| Lead sponsor | Hospital Universitario Infanta Cristina |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 31 January 2019 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Resection of inferior vena cava and reconstruction
Conditions studied
- Neoplasms — all drugs for Neoplasms →
- Surgery--Complications — all drugs for Surgery--Complications →
- Vascular Diseases — all drugs for Vascular Diseases →
- Vein Disease — all drugs for Vein Disease →
Sponsor
Hospital Universitario Infanta Cristina
Who can join
Adults 18 to 80, any sex, with Neoplasms or Surgery--Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The involvement of the inferior vena cava (IVC) in advanced abdominal tumors is a surgical challenge, given the high postoperative morbidity and poor long-term prognosis. The goal was to analyze the experience, perioperative management, and results. Investigators have evaluated short and long-term results of surgical resections of tumors with associated inferior vena cava resection performed between 2012 and 2018.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04154761
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasms
Currently open trials in the same condition.
- NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
- NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting
Other Hospital Universitario Infanta Cristina trials
Trials by the same sponsor.
- NCT06948864 — Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04154761 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Infanta Cristina
- Last refreshed: 8 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04154761.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing